Dyslipidemia is a condition caused by abnormal fluctuation in the levels of cholesterol as well as lipoproteins such as High-Density Lipoprotein (HDL) and Low-Level Lipoprotein (LDL). Besides tagging them as an important component of the living cells, their existence in escalated levels can increase the risk of getting a heart attack or any other major health issue.
There could be numerous rationale behind having undesirable levels of cholesterol such as for overweight or obesity, diabetes, hypothyroidism, or the reasons could also be associated with family history as well as the side effects of other medications.
The treatment for dyslipidemia varies depending on the severity. Initial medications such as statins are recommended as first-line treatment of severe dyslipidemia, along with lifestyle changes including exercise, diet control, maintaining healthy body weight is also suggested in order to have an effective hold on the disease.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/dyslipidemia-market
The Dyslipidemia market report also covers emerging drugs, current treatment practices, Dyslipidemia market share of the individual therapies, current and forecasted Dyslipidemia Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Dyslipidemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Dyslipidemia Market Key Facts
According to the study published by Brian et al., in 2011-2012, approximately one in five children and adolescents aged 8 to 17 years had an adverse lipid concentration of TC, HDL-C, or non-HDL-C, and slightly more than 1 in 10 had either borderline high or high BP. The prevalence of dyslipidemia modestly decreased between 1999-2000 and 2011-2012, but either high or borderline high BP remained stable.
According to NCHS (National Center for Health Statistics), NHANES (National Health and Nutrition Examination Survey) estimated that in the United States, approximately 12.4% of adults had high total cholesterol, and an estimated 18.4% of adults had low HDL cholesterol. Overall, the prevalence of high total cholesterol was higher in adults aged 40–59 (17.1%) than in those aged 20–39 (7.9%) and 60 and over (12.5%).
According to DelveInsight’s analysis, females are affected more as compared to males, in the case of Dyslipidemia.
Key Benefits of Dyslipidemia Market Report
Dyslipidemia market report provides an in-depth analysis of Dyslipidemia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
The Dyslipidemia market report will help in developing business strategies by understanding the Dyslipidemia Market trends & developments, key players, and future market competition that will shape and drive the Dyslipidemia market in the upcoming years.
The Dyslipidemia market report covers Dyslipidemia current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Dyslipidemia market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Dyslipidemia market size is anticipated to increase during the study period owing to the increasing prevalent population of Dyslipidemia and the expected launch of emerging drugs in the 7MM
The Dyslipidemia market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Dyslipidemia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Dyslipidemia Market Trends of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
The Dyslipidemia epidemiology section covers insights about the historical and current Dyslipidemia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Dyslipidemia Drugs Uptake and Key Market Players
The Dyslipidemia Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dyslipidemia market or expected to get launched in the market during the study period. The analysis covers Dyslipidemia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The available therapeutics treatment options in Dyslipidemia Landscape aims to provide a cure to the patients suffering from this indication; however, there are several challenges that are yet to be tackled. Companies worldwide are involved in the therapeutics development for Dyslipidemia.
Eli Lilly and Company
And many others.
Dyslipidemia Therapies covered in the report include:
And many others
Table of Content
1. Key Insights
2. Executive Summary
3. Dyslipidemia Competitive Intelligence Analysis
4. Dyslipidemia Market Overview at a Glance
5. Dyslipidemia Disease Background and Overview
6. Dyslipidemia Patient Journey
7. Dyslipidemia Epidemiology and Patient Population
8. Dyslipidemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Dyslipidemia Unmet Needs
10. Key Endpoints of Dyslipidemia Treatment
11. Dyslipidemia Marketed Products
12. Dyslipidemia Emerging Therapies
13. Dyslipidemia Seven Major Market Analysis
14. Attribute Analysis
15. Dyslipidemia Market Outlook (7 major markets)
16. Dyslipidemia Access and Reimbursement Overview
17. KOL Views on the Dyslipidemia Market.
18. Dyslipidemia Market Drivers
19. Dyslipidemia Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Latest Reports By DelveInsight
Dyslipidemia Pipeline Insights
Dyslipidemia Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Dyslipidemia market.
Healthcare Blogs –
Bone Cancer Market Growth
Bone Cancer is a complex disease that encompasses several types of cancer such as Osteosarcoma, Chondrosarcoma, EwingSarcoma, and many others, that often results in severe health complications, physical and financial burden on the affected person. The overall incidence and prevalence of Bone Cancer are slightly less as compared to other cancers but it is associated with significant mortality and morbidity. To improve the health outcomes for the people affected with bone cancer, some of the key companies such as Bayer Pharmaceuticals, GSK, Exelixis, Eisai EMEA, and several others are exploring potential therapies for bone cancer. For more details, visit: Key Companies in Bone Cancer Market
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States